Welcome to our dedicated page for Rein Therapeutics SEC filings (Ticker: RNTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Rein Therapeutics, Inc. (RNTX) SEC filings page brings together the company’s official U.S. Securities and Exchange Commission disclosures, including current reports on Form 8-K and registration statements that describe its clinical programs, financing arrangements, and regulatory milestones. These documents provide primary-source detail on how the clinical-stage biopharmaceutical company is advancing therapies for idiopathic pulmonary fibrosis (IPF) and other orphan pulmonary and fibrosis indications.
Among the most relevant filings for RNTX are multiple Form 8-K reports. These include descriptions of the Phase 2 RENEW trial of LTI-03 in IPF, FDA communications regarding a clinical hold and its subsequent resolution, and regulatory authorizations from European agencies for trial sites in the United Kingdom, Germany, and Poland. Other 8-Ks outline the structure and terms of a Pre-Paid Advance Agreement and a Standby Equity Purchase Agreement with an affiliate of Yorkville Advisors, as well as later disclosure that Rein elected to terminate these agreements after taking specified advances and without incurring penalties.
Investors can also review the company’s S-1 registration statement, which summarizes Rein’s business overview, risk factors, and details of the Yorkville standby equity facility, including the number of shares registered for potential resale. Together, these filings explain how Rein describes its lead candidate LTI-03, its second candidate LTI-01 for loculated pleural effusions, and the associated orphan drug and Fast Track designations.
On Stock Titan, AI-powered tools can help interpret lengthy RNTX filings by highlighting key sections on clinical trial design, regulatory status, and financing terms. Users can quickly locate information on material agreements, capital structure changes, and important clinical or regulatory events disclosed in Rein Therapeutics’ SEC documents.
Rein Therapeutics (RNTX) filed a Form 4 disclosing a routine equity grant to independent director Alan A. Musso. On 07/23/2025 Musso received 17,500 non-qualified stock options exercisable at $1.55 per share, equal to the grant-date market price. The award vests 100 % on the earlier of 07/23/2026 or the company’s 2026 annual meeting, conditional on continued board service. Following the transaction Musso beneficially owns 17,500 derivative securities and no additional common shares were reported. Ownership is held directly; no indirect holdings were disclosed.
No sale of shares, cashless exercise, or change in overall insider ownership occurred, so immediate dilution is de-minimis. The filing is primarily administrative, aligning director incentives with shareholders.
Rein Therapeutics, Inc. (RNTX) – Form 4 insider filing
Director William C. Fairey reported the grant of 17,500 non-qualified stock options on 07/23/2025. The options carry a $1.55 exercise price and will vest in full on the earlier of 07/23/2026 or the company’s 2026 annual shareholder meeting, provided the director remains in service. The options expire on 07/22/2035. No common shares were bought or sold and the filing shows direct ownership of the new derivative position. This appears to be routine board compensation and does not alter the company’s capital structure or provide guidance on operating performance.
Rein Therapeutics (RNTX) filed a Form 4 on 23-Jul-2025 reporting the first equity award to director Reinhard J. Ambros. The filing shows a single transaction: a stock-option grant for 17,500 common shares at an exercise price of $1.55 per share. The option vests 100% on the earlier of 23-Jul-2026 or the company’s 2026 annual meeting, contingent on continued service. No sales or open-market purchases were disclosed, and Table I lists no direct common-stock holdings. After the grant, Ambros’ beneficial ownership consists of 17,500 derivative securities held directly.
The transaction is routine director compensation and represents a modest potential dilution relative to RNTX’s total share count (not provided in the filing). Because it is an A code (award) rather than an open-market buy, it should not be interpreted as an active insider purchase. However, it does increase insider alignment by giving the director upside participation tied to share-price performance above $1.55.
Rein Therapeutics (NASDAQ: RNTX) has adjourned its 2025 Annual Meeting of Stockholders originally scheduled for June 24, 2025 because a quorum was not reached.
The meeting will reconvene virtually on Wednesday, July 23, 2025 at 9:00 a.m. ET. The record date remains May 5, 2025, and no changes have been made to the proposals outlined in the definitive proxy filed on May 12, 2025. Proxies already submitted will remain valid unless revoked, and shareholders may continue to vote or change prior votes until 11:59 p.m. ET on July 22, 2025.
The company urges all eligible shareholders who have not yet voted to do so to ensure quorum and facilitate governance decisions.
Rein Therapeutics (NASDAQ: RNTX) announced the adjournment of its 2025 Annual Meeting of Stockholders originally scheduled for June 24, 2025. The meeting has been rescheduled to July 23, 2025 due to failure to achieve a quorum.
Key details of the adjournment:
- Original meeting date: June 24, 2025
- New meeting date: July 23, 2025
- Record date remains: May 5, 2025
- Purpose: To allow additional time for stockholders to vote on proposals outlined in the proxy statement filed May 12, 2025
The Form 8-K was filed by President and CEO Brian Windsor, Ph.D. from the company's Austin, Texas headquarters. This development indicates potential challenges in securing sufficient shareholder participation for important corporate governance matters.